Newly diagnosed lung cancer patients are half as likely to die of the disease if they take a Merck drug alongside standard chemotherapy, according to new trial data that eclipsed doctors’ expectations.

The trial, which compared a combination of chemo and Merck’s blockbuster Keytruda against chemo alone, found that patients in the combo group were 51 percent more likely to be alive after one year. Those getting Merck’s drug were also 48 percent less likely to have their cancer progress in the same period.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • I had to stop the keytruda. I have developed hypothyroidism and within the last couple months acute renal failure as a result of taking this medication. Still on high-dose steroids to try to correct the condition without help or Improvement so far

    • So sorry to hear that. My husband himself just started keytruda along with pem traxade. His first dose went well and he actually said that he felt better then he normally does so we’re praying that this works he’s now on maintenance therapy and has been for two years we realize the devastating possible side effects but feel the benefits far outweigh the risk for now we will keep you in our prayers good luck and I hope the side effects can be reversed keep your faith in God he is the ultimate position our faith is what has gotten us this far God bless

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy